Omnicell (NASDAQ:OMCL) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note released on Thursday.

OMCL has been the topic of a number of other research reports. Barclays raised Omnicell from an underweight rating to an equal weight rating and lifted their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Bank of America upped their price target on shares of Omnicell from $34.00 to $44.00 and gave the company a buy rating in a research note on Friday, August 2nd. Wells Fargo & Company lifted their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an equal weight rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a neutral rating in a research report on Friday, August 23rd. Finally, Benchmark reiterated a buy rating and issued a $38.00 target price on shares of Omnicell in a report on Monday, July 15th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $37.83.

Omnicell Price Performance

OMCL stock opened at $44.62 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The company’s fifty day moving average price is $39.21 and its 200-day moving average price is $32.28. Omnicell has a one year low of $25.12 and a one year high of $53.37. The company has a market capitalization of $2.05 billion, a PE ratio of -97.00, a price-to-earnings-growth ratio of 49.47 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same quarter in the prior year, the firm earned $0.29 EPS. The business’s revenue was down 7.4% on a year-over-year basis. On average, equities analysts anticipate that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after buying an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC increased its position in shares of Omnicell by 16.0% during the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after purchasing an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after purchasing an additional 3,570 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after purchasing an additional 909,480 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.